AFFILIATIONS
1 Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada, University of Montreal, Montreal, Quebec, Canada
2 Jewish General Hospital, Montreal, Quebec, Canada, McGill University, Montreal, Quebec, Canada
3 Quebec Kinesiologist Federation, Montreal, Quebec, Canada
4 Faculty of Nursing, Montreal, Quebec, Canada, Maisonneuve-Rosemont Hospital Research Centre, Montreal, Quebec, Canada
5 Maisonneuve-Rosemont Hospital Research Centre, Montreal, Quebec, Canada, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada, Quebec CML-MPN Research Group, Montreal, Quebec, Canada, University of Montreal, Montreal, Quebec, Canada
6 Quebec CML-MPN Research Group, Montreal, Quebec, Canada
7 Quebec CML-MPN Research Group, Montreal, Quebec, Canada
8 Maisonneuve-Rosemont Hospital Research Centre, Montreal, Quebec, Canada, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada, Quebec CML-MPN Research Group, Montreal, Quebec, Canada, University of Montreal, Montreal, Quebec, Canada
9 Jewish General Hospital, Montreal, Quebec, Canada, McGill University, Montreal, Quebec, Canada, Quebec CML-MPN Research Group, Montreal, Quebec, Canada
10 Maisonneuve-Rosemont Hospital Research Centre, Montreal, Quebec, Canada, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada, Quebec CML-MPN Research Group, Montreal, Quebec, Canada, University of Montreal, Montreal, Quebec, Canada
ABSTRACT
Background: The MPN-FIT trial demonstrated that a structured exercise intervention may reduce symptom burden and disease markers in patients with myeloproliferative neoplasms (MPN) (Ouellet et al, Blood Adv, 2026). However, the long-term sustainability of physical activity and its effects on patient-reported and clinical outcomes remain unclear. We aimed to evaluate physical activity levels 12 months after participation in the MPN-FIT pilot randomized controlled trial (RCT), to examine associations with symptom burden and quality of life (QoL), and to explore factors associated with maintaining high exercise levels at follow-up.
Methods: This longitudinal observational follow-up study included patients with essential thrombocytosis (ET), polycythemia vera (PV) or myelofibrosis (MF) who had participated in the MPN-FIT pilot trial. In the original 12-week RCT, participants were either assigned to the FIT intervention, which included personalized aerobics, resistance, and flexibility training, or to a control group, which maintained its usual exercise levels. After the intervention, all participants received exercise recommendations and were encouraged to be physically active. At 12 months post-intervention, all participants were contacted and invited to participate in the follow-up study. Patients underwent peripheral blood sampling (CBC, CRP, LDH, ferritin) and completed patient-reported outcome (PRO) questionnaires assessing symptom burden and QoL (MPN-10, NIH PROMIS). Exercise level was evaluated using a modified Godin Leisure-Time Exercise Questionnaire (GLTEQ), with high physical activity defined as a GLTEQ score ≥ 14. Within-group changes in exercise levels from baseline to follow-up and between-group differences in PROs/biomarkers were assessed using Wilcoxon signed-rank and Mann–Whitney U tests respectively; exploratory predictors of exercise maintenance were evaluated using logistic regressions.
Results: Thirty-five of the 47 original MPN-FIT trial participants were included (FIT, n=17; control, n=18). Eleven participants were unreachable, and one was unable to participate due to hospitalization. Between the end of the intervention and follow-up, disease progression to MF occurred in 1 of 17 FIT (5.9%) and 1 of 18 control participants (5.3%). Two major thrombotic or hemorrhagic events occurred, both among participants originally assigned to the control group, while no events occurred in FIT patients. In the overall cohort, median GLTEQ score increased significantly from 3.00 at baseline to 15.00 at 12-month follow-up (p=0.008). The increase was significant among patients originally assigned to the FIT group (3.00 to 17.00; p = 0.02), but not in those from the control group (3.00 to 10.50; p = 0.1). Variations in biomarkers and PROs did not significantly differ between original study groups. However, significantly greater improvements in depression (p = 0.02) and anxiety (p = 0.02) were observed in patients with high physical activity at follow-up compared to those with lower exercise levels. Exploratory analyses identified partnered status as a predictor of maintaining high activity levels at follow-up (OR 12.67, p = 0.03). Higher educational status was also associated with greater odds of remaining active (OR 4.96, p = 0.049), whereas patients with MF had lower odds than those with ET or PV (OR 0.17, p = 0.05); neither age nor sex was correlated with activity maintenance.
Conclusions: To our knowledge, this is the first study to assess long-term effects of an exercise intervention in MPN patients. Our findings show that exercise engagement was sustained up to 12 months after the FIT intervention, suggesting a lasting behavioral effect of structured exercise. Although outcomes did not significantly differ between FIT and control patients, achieving higher exercise levels, regardless of original group assignment, was associated with improved QoL. The small sample size and increased physical activity in both groups may have limited detection of between-group effects. Recognizing partnered status, educational level, and MPN subtype as potential determinants of physical activity maintenance could help identify patients requiring additional support to sustain activity programs, facilitating a personalized approach to care. Larger controlled studies are needed to better characterize the long-term effects of structured physical activity in patients with MPN.
DISCLOSURES
Marie Ouellet, MD: No relevant conflicts of interest to declare.